Current ideas on the pathogenesis of renal injury in preeclampsia


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Renal injury in preeclampsia (PE) remains an urgent problem in modern obstetrics and nephrology, which is due to its high prevalence (2-14% of all pregnancies) and outcome unpredictability. The pathogenesis of renal injury in PE, like a balance of pro- and antiangiogenic factors that are today considered to be one of the major pathogenetic mechanisms of PE, has not been practically investigated. The paper presents an update on the pathogenesis of renal injury in PE and shows the impact of a soluble fms-like tyrosine kinase-1/vascular endothelial growth factor system imbalance on the clinical manifestations of nephropathy in PE.

Full Text

Restricted Access

About the authors

L. I Merkusheva

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: milka0013@mail.ru
nephrologist, therapeutic department

N. L Kozlovskaya

I.M. Sechenov First Moscow State Medical University

Email: nkozlovskaya@yandex.ru
MD, PhD, Prof., Professor at the Department of Nephrology and Hemodialysis, Faculty for Postgraduate Training of Physicians

References

  1. Hertig A., Watnick S., Strevens H., Boulanger H., Berkane N., Rondeau E. How should women with pre-eclampsia be followed up? New insights from mechanistic studies. Nat. Clin. Pract. Nephrol. 2008; 4(9): 503-9.
  2. Noris M., Perico N., Remuzzi G. Mechanisms of disease: pre-eclampsia. Nat. Clin. Pract. Nephrol. 2005; 1(2): 98-114.
  3. James P.R., Nelson-Piercy C. Management of hypertension before, during and after pregnancy. Heart. 2004; 90(12): 1499-504.
  4. Levine R.J., Maynard S.E., Qian C., Lim K.H., England L.J., Yu K.F. et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 2004; 350(7): 672-83.
  5. Maynard SE, Min JY, Lim KH et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 2003; 111(5): 649-58.
  6. ТарееваИ.Е. Нефрология. Руководство для врачей. М.: Медицина;2000: 464-73.
  7. Karumanchi S.A., Maynard S.E., Stillman I.E., Epstein F.H., Sukhatme V.P. Preeclampsia: a renal perspective. Kidney Int. 2005; 67(6): 2101-13.
  8. Eremina V., Sood M., Haigh J., Nagy A., Lajoie G., Ferrara N. et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases J. Clin. Invest. 2003; 111(5): 707-16.
  9. Chappal L.C., Enye St., Seed P., Briley A.L., Poston L., Shennan A.H. Adverse perinatal outcomes and risk factors for preeclampsia in women with chronic hypertension: a prospective study. Hypertension. 2008; 51(4): 1002-9.
  10. Aita K., Etoh M., Hamada H., Yokoyama C., Takahashi A., Suzuki T. et al. Acute and transient podocyte loss and proteinuria in preeclamsia. Nephron. Clin. Pract. 2009; 112(2): c65-70.
  11. Garovic V.D., Wagner S.J., Turner S.T., Rosenthal D.W., Watson W.J., Brost B.C. et al. Urinary podocyte excretion as a marker for preeclampsia. Am. J. Obstet. Gynecol. 2007; 196(4): 320. e1-7.
  12. Craici I.M., Wagner S.J., Bailey K.R., Fitz-Gibbon P.D., Wood-Wentz C.M., Turner S.T. et al. Podocyturia predates proteinuria and clinical features of preeclampsia: longitudinal prospective study. Hypertension. 2013; 61(6): 1289-96.
  13. Cohen A.W., Burton N.G. Nephrotic syndrome due to preeclamptic nephropathy in hydatidiform mole and coexistent fetus. Obstet. Gynecol. 1979; 53(1): 130-13.
  14. Müller-Deile J., Worthmann K., Saleem M., Tossidou I., Haller H., Schiffer M. The balance of autocrine VEGF-A and VEGF-C determines podocyte survival. Am. J. Physiol. Renal Physiol. 2009; 297(6): F1656-67.
  15. National Kidney Foundation. Kidney Disease Outcome Quality Initiative (KDOQI). Clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am. J. Kidney Dis. 2007; 49(2, Suppl.2): S12-154.
  16. Mith М.С., Moran P., Ward M.K., Davison J.M. Assessment of glomerular filtration rate during pregnancy using the MDRD formula. BJOG: Br. J. Obstet. Gynaecol. 2008; 115(1): 109-12.
  17. Scaffer N.K., Dill L.V., Cadden J.F. Uric acid clearance in normal pregnancy and preeclampsia. J. Clin. Invest. 1943; 22(2): 201-6.
  18. Simon M., Gröne H.J., Jöhren O., Kullmer J., Plate K.H., Risau W., Fuchs E. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am. J. Physiol. 1995; 268(2, Pt 2): F240-50.
  19. Nisell H., Lintu H., Lunell N.O., Möllerström G., Pettersson E. Blood pressure and renal function seven years after pregnancy complicated by hypertension. Br. J. Obstet. Gynaecol. 1995; 102(11): 876-81.
  20. Kearney J.B., Kappas N.C., Ellerstrom C., DiPaola F.W., Bautch V.L. The VEGF receptor flt-1 (VEGFR-1) is a positive modulator of vascular sprout formation and branching morphogenesis. Blood. 2004; 103(12): 4527-35.
  21. Muller-Deile J., Schiffer M. Renal involvement in preeclampsia: similarities to VEGF ablation therapy. J. Pregnancy. 2011; 2011: 176973.
  22. Ballermann B.J. Glomerular endothelial cell differentiation. Kidney Int. 2005; 67(5): 1668-71.
  23. Rodie V., Freeman D.J., Sattar N., Greer I.A. Pre-eclampsia and cardiovascular disease: metabolic syndrome of pregnancy? Atherosclerosis. 2004; 175(2):189-202.
  24. Vikse B.E., Irgens L.M., Leivestad T., Skjaerven R., Iversen B.M. Preeclampsia and the risk of end-stage renal disease. N. Engl. J. Med. 2008; 359(8): 800-9.
  25. Abbate M., Zoja C., Remuzzi G. How does proteinuria cause progressive renal damage? J. Am. Soc. Nephrol. 2006; 17(11): 2974-84.
  26. Nakagawa T., Lan H.Y., Zhu H.J., Kang D.H., Schreiner G.F., Johnson R.J. Differential regulation of VEGF by TGF-beta and hypoxia in rat proximal tubular cells. Am. J. Physiol. Renal Physiol. 2004; 287(4): F658-64.
  27. Reiter L., Brown M.A., Whitworth J.A. Hypertension in pregnancy: the incidence of underlying renal disease and essential hypertension. Am. J. Kidney Dis. 1994; 24(6): 883-7.
  28. Duley L., Gülmezoglu A.M., Henderson-Smart D.J., Chou D. Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. Cochrane Database Syst. Rev. 2010; (11): CD000025.
  29. Stillman I.E., Karumanchi S.A. The glomerular injury of preeclampsia. J. Am. Soc. Nephrol. 2007; 18(8): 2281-4.
  30. Yang J.C., Haworth L., Steinberg S.M., Rosenberg S.A., Novotny W. A randomized double-blind placebo controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer. Proc. Am. Soc. Clin. Oncol. 2002; 21: abstr.15.
  31. Patel T.V., Morgan J.A., Demetri G.D., George S., Maki R.G., Quigley M., Humphreys B.D. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria indused by the multitargeted kinase inhibitors sunitinib and sorafenib. J. Natl. Cancer Inst. 2008; 100(4): 282-4.
  32. Li B., Ogasawara A.K., Yang R., Wei W, He G.W., Zioncheck T.F. et al. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension. 2002; 39(6): 1095-100.
  33. Hay J.E. Liver disease in pregnancy. Hepatology. 2008; 47(3): 1067-76.
  34. Strevens H., Wide-Swensson D., Hansen A., Horn T., Ingemarsson I., Larsen S. et al. Glomerular endotheliosis in normal pregnancy and preeclampsia. BJOG: Br. J. Obstet. Gynaecol. 2003; 110(9): 831-6.
  35. Lima F., Khamashta M.A., Buchanan N.M., Kerslake S., Hunt B.J., Hughes G.R. A study of sixty pregnancies in patients with antiphospholipid syndrome. Clin. Exp. Rheumatol.1996; 14(2): 131-6.
  36. Suga S., Kim Y.G., Joly A., Puchacz E., Kang D.H., Jefferson J.A. et al. Vascular endothelial grown factor (VEGF121) protects rats from renal infarction in thrombotic microangiopathy. Kidney Int. 2001; 60(4): 1297-308.
  37. Ballermann B.J. Glomerular endothelial cell differentiation. Kidney Int. 2005; 67(5): 1668-71.
  38. Robinson E.S., Matulonis U.A., Ivy P., Berlin S.T., Tyburski K., Penson R.T., Humphreys B.D. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial grown factor receptor inhibitor. Clin. J. Am. Soc. Nephrol. 2010; 5(3): 477-83.
  39. Yang R., Ogasawara A.K., Zioncheck T.F., Ren Z., He G.W., DeGuzman G.G. et al. Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats. Hypertension. 2002; 39(3): 815-20.
  40. Okuda Y., Tsurumaru K., Suzuki S., Miyauchi T., Asano M., Hong Y. et al. Hypoxia and endothelin-1 induce VEGF production in human vascular smooth muscle cells. Life Sci. 1998; 63(6): 477-84.
  41. Quaggin S.E., Coffman T.M. Toward a mouse model of diabetic nephropathy: is endothelial nitric oxide synthase the missing link? J. Am. Soc. Nephrol. 2007; 18(2): 364-6.
  42. Gaber L.W., Spargo B.H. Pregnancy-induced nephropathy: The significance of focal segmental glomerulosclerosis. Am. J. Kidney Dis. 1987; 9(4): 317-23.
  43. Garovic V.D., Wagner S.J., Petrovic L.M., Gray C.E., Hall P., Sugimoto H. et al. Glomerular expression of nephrin and synaptopodin, but not podocin, is decreased in kidney sections from women with preeclampsia. Nephrol. Dial. Transplant. 2007; 22(4): 1136-43.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2015 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies